HUBEI PROVINCE, CHINA--(MARKET WIRE)--Sep 21, 2007 -- Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTC BB:BPMA.OB - News), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, announced today that it has appointed Mr. Charles Mo as the third independent director on the Board and Chairman of the Audit Committee, effective September 14, 2007. Mr. Mo’s appointment establishes the Benda Board as independent; Benda now satisfies all NASDAQ corporate governance requirements.
